SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITP

Key Points SARS-CoV-2 vaccines are generally safe in patients with preexisting ITP but thrombocytopenia exacerbation may occur and requires monitoring. Splenectomy and past use of 5 or more therapies predict higher risk of worsening thrombocytopenia in ITP patients post-SARS-CoV-2 vaccine.

[1]  D. Grady.  A Few Covid Vaccine Recipients Developed a Rare Blood Disorder. , 2021, Brazilian Journal of Implantology and Health Sciences.

[2]  M. Ebbo,et al.  Safety of anti‐SARS‐CoV‐2 vaccination for patients with immune thrombocytopenia , 2021, British journal of haematology.

[3]  K. Khunti,et al.  Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study , 2021, BMJ.

[4]  S. de Lusignan,et al.  First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland , 2021, Nature Medicine.

[5]  D. Kuter.  Exacerbation of immune thrombocytopenia following COVID‐19 vaccination , 2021, British journal of haematology.

[6]  Ravi Goud,et al.  Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the Vaccine Adverse Event Reporting System (VAERS) , 2021, Vaccine.

[7]  D. Goldblatt,et al.  Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination , 2021, The New England journal of medicine.

[8]  Eun-Ju Lee,et al.  Thrombocytopenia following Pfizer and Moderna SARS‐CoV‐2 vaccination , 2021, American journal of hematology.

[9]  J. Mascola,et al.  Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.

[10]  P. Dormitzer,et al.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.

[11]  J. Bussel,et al.  Updated international consensus report on the investigation and management of primary immune thrombocytopenia. , 2019, Blood advances.

[12]  Jiří Mayer,et al.  Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo‐controlled trials , 2018, American journal of hematology.

[13]  J. Kelton,et al.  The effect of rituximab on vaccine responses in patients with immune thrombocytopenia. , 2013, Blood.

[14]  L. Abenhaim,et al.  A case-control study to assess the risk of immune thrombocytopenia associated with vaccines. , 2012, Blood.

[15]  D. Cooper,et al.  The incidence and prevalence of thyroid autoimmunity , 2012, Endocrine.

[16]  J. George,et al.  Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. , 2009, Blood.

[17]  W. Borkowsky,et al.  Role of molecular mimicry of hepatitis C virus protein with platelet GPIIIa in hepatitis C-related immunologic thrombocytopenia. , 2008, Blood.

[18]  J. George,et al.  Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial , 2008, The Lancet.

[19]  J. Bussel,et al.  Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. , 2007, The New England journal of medicine.

[20]  J. Leonard,et al.  The efficacy and safety of B‐cell depletion with anti‐CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura , 2004, British journal of haematology.

[21]  S J Gange,et al.  Epidemiology and estimated population burden of selected autoimmune diseases in the United States. , 1997, Clinical immunology and immunopathology.

[22]  F. Oski,et al.  Effect of live measles vaccine on the platelet count. , 1965, The New England journal of medicine.

[23]  J. Stockman.  Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial , 2010 .